Migraine is a pressing issue for many hampering their day to day lives. It was a great news for patients with migraine just few months back when the US Food and Drug Administration approved the first treatment to target calcitonin-gene-related peptides (CGRP). They finally got a drug to abate migraine. However a recent study conducted has shown that hardly any patients are aware of the CGRP therapies and are therefore not taking the medications to tackle migraine. The study has been conducted by Health Union LLC which revealed that only one-third of the respondents were aware of this therapy. CGRPs